Medtech Deals 'Meaningfully Rebound' in Q1

According to a recent PitchBook report, medtech M&A is on the rise, especially with cardiovascular tech and surgical robotics.Key points to note about this recent shift:▪️ Q1 2024 saw $3.3B in funding, up from $2.8B in Q4 2023▪️ Cardiovascular and surgical robotics led the charge with $2.2B and $1B, respectively, in the past year▪️ About 1/2 of the Q1 funding went to later-stage deals.This surge in deal value suggests there could be a strong rest of the year ahead for manda activity. Stabilizing public medtech valuations could further contribute to this trend, allowing for new opportunities for growth and innovation.Give this Axios article a read for more.Discover more about Louis Lehot and explore additional professional insights on his website: https://louislehot.comExplore Related Content: This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit louislehotattorney.substack.com